This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy.
Reihe
Auflage
Sprache
Verlagsort
Verlagsgruppe
Springer International Publishing
Zielgruppe
Illustrationen
9
15 farbige Abbildungen, 9 s/w Abbildungen
XI, 331 p. 24 illus., 15 illus. in color.
Maße
Höhe: 241 mm
Breite: 160 mm
Dicke: 25 mm
Gewicht
ISBN-13
978-3-319-63756-3 (9783319637563)
DOI
10.1007/978-3-319-63757-0
Schweitzer Klassifikation
Razelle Kurzrock, MD, is Senior Deputy Director for Clinical Science, Chief, Division of Hematology & Oncology, Murray Professor of Medicine, Director, Center for Personalized Cancer Therapy & Clinical Trials Office, University of California, San Diego.
Sandip Patel, MD, is Assistant Professor, Cancer Immunotherapy Program, Experimental Therapeutics (Phase 1 Program), Thoracic Oncology, Division of Hematology & Oncology and Center for Personalized Cancer Therapy, UC San Diego Moores Cancer Center.
